1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Anupam Rasayan India Ltd.

Anupam Rasayan India Ltd.

1,106.10
INR
-2.30
(-0.21%)
19.17EPS
86.79P/E
143.95BMarket Cap
Nov 11Next Earn
Anupam Rasayan India Ltd.
NSE:ANURAS
(National Stock Exchange of India)

Recent

price

1,106.10

P/E

ratio

86.79

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
34.38
50.48
53.35
98.89
105.1
150.71
133.38
127.65
205.96
202.89
Revenue per Share
4.13
4.93
5.32
8.56
15.22
17.44
11.89
8.5
15.09
14.57
Basic EPS, GAAP
-27.61
-20.95
-8.55
-17.59
-31.82
6.88
-60.74
-40.06
-19.59
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
1
2.37
2.43
1.22
1.35
- -
Dividend per Share
43.33
48.29
56.58
157.46
172.26
220.78
251.49
259.28
290.02
- -
Book Value per Share
41.84
46.96
55.3
156.3
171.11
207.98
238.32
245.99
225.66
- -
Tangible Book Value per Share
100
100
100
82
100
104
108
110
113
113
Basic Weighted Avg Shares
3,435
5,044
5,331
8,124
10,508
15,629
14,426
14,023
23,214
22,890
Sales/Revenue/Turnover
17.83
16.16
22.19
18.83
23.31
23.05
20.9
21.35
17.25
16.93
Operating Margin (%)
176
225
287
517
601
711
797
1,023
1,399
1,639
Depreciation Expense
413
492
532
703
1,522
1,808
1,286
933
1,701
1,644
Net Income, GAAP
18.93
23.6
25.76
29.71
31.41
29.52
30.75
19.15
12.66
12.99
Effective Tax Rate (%)
12.03
9.76
9.98
8.65
14.48
11.57
8.91
6.66
7.33
7.18
Profit Margin (%)
792
841
578
6,699
8,516
13,004
9,104
7,647
11,121
- -
Working Capital
2,678
4,623
5,577
2,796
5,140
3,819
2,370
2,230
5,594
- -
LT Debt
4,576
5,071
5,935
15,734
17,268
25,081
29,307
30,817
46,300
- -
Total Equity
- -
6
6.63
6.2
7.32
8.69
5.79
5.73
6.34
- -
Return on Invested Capital (%)
- -
5.86
6.11
6.42
7.4
6.09
3.95
2.58
4.4
- -
Return on Capital (%)
- -
10.76
10.15
6.57
9.22
8.82
5.01
3.33
5.53
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
13,382
- -
LT Borrowings
- -
5,108
- -
LT Finance Leases
- -
486
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
114
114
114
Market Capitalization
150,152
140,136
143,949

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
37,275
- -
Cash, Cash Equivalents & STI
- -
3,995
- -
Accounts Receivable, Net
- -
9,594
- -
Inventories
- -
17,748
- -
Total Current Liabilities
- -
26,154
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
13,382
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.45%
50.24%
Free Cash Flow
- -
-221.3%
-49.82%
Net Income, GAAP
- -
32.25%
82.24%
Sales/Revenue/Turnover
- -
26.62%
65.54%
Total Cash Common Dividend
- -
- -
13.27%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2,542
2,940
3,901
5,002
14,023
2026
4,858
- -
5,124
6,358
23,214
2027
6,550
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.36
1.51
2.57
4.06
8.5
2026
3.1
- -
4.31
3.75
15.09
2027
3.39
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.22
2026
- -
- -
- -
- -
1.35
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Anupam Rasayan India Limited specializes in the custom synthesis and manufacturing of advanced specialty chemicals. The company develops and produces a diverse range of materials for life science sectors, encompassing agrochemical intermediates and active ingredients, antibacterial and UV protection compounds for personal care, and key starting materials for active pharmaceutical ingredients. Additionally, it offers various other specialty chemicals, including high-performance pigments, dyes, and polymer additives. Anupam Rasayan is actively expanding its footprint into emerging areas such as electronic chemicals and high-performance materials for defense, aerospace, and semiconductor industries. Leveraging expertise in complex chemistries and advanced manufacturing, including continuous and flow chemistry technology, the firm serves a broad base of Indian and international clients across Europe, Japan, Singapore, China, and North America. Founded in 1984 and headquartered in Surat, India, the company maintains robust R&D capabilities and strategic backward integration. Recent achievements include consistent financial performance, a significant order book extending over several years, and new molecule launches, reflecting its commitment to innovation and market growth. The company is also focused on sustainability, with initiatives aimed at achieving energy neutrality by 2027.